Yonalink

As we ready ourselves for 2025, the clinical trials industry finds itself at a critical turning point. While new technologies and innovative methodologies promise to revolutionize the field, a persistent resistance to change continues to hold progress back. In this article, Yonalink CEO Iddo Peleg explores key predictions for how clinical trials are set to evolve in 2025 and beyond. He examines industry trends that have taken hold since the COVID-19 pandemic as well as the way AI is creating new ways to increase efficiencies and reduce costs. Are you prepared for 2025? Do you have other thoughts on where the industry is headed? We'd love to hear them! https://lnkd.in/gQtgRyym

Wishing you and yours a happy holiday season and a wonderful new year!

Uterine cancer is now the deadliest gynecologic cancer in the U.S., projected to claim the lives of over 13,000 American women in 2024. Sadly, the impact is far from equal. Black and Hispanic women face disproportionately higher rates of advanced diagnoses and lower survival rates. Addressing these challenges requires earlier diagnosis and more equitable access to both routine medical care and clinical trials as a care option. Including underrepresented populations in trials ensures that new treatments are effective for everyone. At Yonalink, we're committed to making clinical trials more accessible - it's at the core of everything we do. Let's talk about ways to expand access in your next clinical trial, with our network of over 7,000 medical centers available for EHR-to-EDC data streaming.

Enabling different complex health systems to communicate effectively, often referred to as interoperability, has been a longstanding challenge. Enter HL7 FHIR, a transformative technology designed to bridge these gaps. While progress has been slow, its potential is undeniable. In this article, explore: - Why FHIR is critical for clinical trials - How it enhances real-world evidence integration - The key hurdles slowing its adoption Dive into the possibilities FHIR brings to healthcare innovation! https://lnkd.in/dH8tcHx9

After years of losing market share in the clinical trials industry, the UK is rewriting its playbook, with a strategic overhaul that initiators expect will be a game changer for the global research community. Hailed as the biggest regulatory overhaul in 20 years, the MHRA’s new measures aim to make clinical trials faster, more transparent, and more inclusive—all without compromising safety. The regulations will only take effect after a 12-month implementation process has been completed, but proponents are already excited about the upcoming changes, including: 1️⃣ A reduction in application review times to as little as 30 days, with decisions finalized within 10 days after all information is submitted. 2️⃣ A legal mandate requiring trials to be registered on WHO-approved public platforms, with results shared within 12 months. 3️⃣Provisions for decentralized and adaptive trials to encourage more efficient methodologies. 4️⃣ Increased opportunity for diversity and inclusion in the UK's clinical trials. By refining its clinical trial framework, the UK is showing its desire to become a leading destination for clinical trials and an inclusive research environment that better serves both researchers and patients.

𝗜𝗻 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀, 𝘁𝗵𝗲 𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝘁𝗼 𝗽𝗶𝘃𝗼𝘁 𝗶𝘀 𝗻𝗼𝘁 𝗮 𝗹𝘂𝘅𝘂𝗿𝘆 - 𝗶𝘁'𝘀 𝗮 𝗻𝗲𝗰𝗲𝘀𝘀𝗶𝘁𝘆. From protocol adjustments to regulatory updates, sponsors and CROs must be agile to ensure trial success. Embracing change is essential to staying ahead. As the industry evolves, so do the tools and processes that drive efficiency and accuracy. One such opportunity lies in streamlining data collection and management through EHR to EDC solutions. Are you ready to explore how these innovations can transform your clinical trials? Let’s discuss how Yonalink can help you stay at the forefront of clinical operations.

"EHR-to-EDC isn't a feature. It's a product." In their recent podcast conversation, Dan Sfera, the Clinical Trials Guru, and Yonalink CEO Iddo Peleg, break down some of the biggest problems in clinical trials today and discuss sensitive topics including: 💠 Who benefits most from clinical trial inefficiencies? Who stands to gain by improving the data transfer process? 💠 Why are highly educated clinical trial staff still doing tedious, boring data copying? 💠 Why EHR-to-EDC streaming can't easily be integrated into legacy EDCs, and what can we do about it? ...and more. Take 30 minutes to listen to the conversation, and let us know your thoughts! https://lnkd.in/dDvmBWKY

𝗨𝗽 𝘁𝗼 𝟱𝟬 𝗽𝗲𝗿𝗰𝗲𝗻𝘁 𝗼𝗳 𝗰𝗮𝗻𝗰𝗲𝗿𝘀 𝗮𝗿𝗲 𝗽𝗿𝗲𝘃𝗲𝗻𝘁𝗮𝗯𝗹𝗲. 𝗝𝘂𝘀𝘁 𝗹𝗲𝘁 𝘁𝗵𝗮𝘁 𝘀𝗶𝗻𝗸 𝗶𝗻 𝗳𝗼𝗿 𝗮 𝘀𝗲𝗰𝗼𝗻𝗱. We all know that tobacco smoke is a major carcinogen. Smoking is the top preventable risk factor, claiming over 8 million lives annually. However, there are other common causes of cancer, and awareness can mean prevention. 𝗔𝗹𝗰𝗼𝗵𝗼𝗹: Classified as a Group 1 carcinogen, alcohol is linked to 7 types of cancer, including breast and liver cancers. It contributes to 740,000 new cancer cases each year. 𝗢𝗯𝗲𝘀𝗶𝘁𝘆 𝗮𝗻𝗱 𝗶𝗻𝗮𝗰𝘁𝗶𝘃𝗶𝘁𝘆: Excess body weight and lack of physical activity are major risk factors for various cancers, including breast and colorectal cancers. Infections: Hepatitis and HPV contribute to 25% of cancer cases in low- and middle-income countries. Vaccines can help prevent these cancers. 𝗥𝗮𝗱𝗶𝗮𝘁𝗶𝗼𝗻: Exposure to the sun and other sources of UV rays are extremely harmful, especially when the exposure is at a young age. Sunscreen and staying out of direct sunlight can dramatically reduce your risk of skin cancer. Pharma companies worldwide are working hard to develop ways to prevent and treat cancer. It's our responsibility to help by eliminating risk factors and protecting ourselves whenever possible. Together, we can prevent cancer. #CancerPrevention #HealthAwareness #PublicHealth

Clinical trials come with their own language—an alphabet soup of acronyms like EHRs, EDCs, CRAs, CROs, CRCs, FDA, EMEA, ePRO, and hundreds more. On top of these acronyms, trial staff must also remember the details of the protocol, the nuances of using multiple data capture and management systems, treatment instructions, calendar appointments, regulatory requirements, a multitude of system logins and SO much more. It's time to ease the burden on clinical trial staff with automatic EHR-to-EDC streaming that reduces the need for manual data transfer. Let's improve the lives of clinical trial staff and give them more time to focus on what they do best: bring life-changing treatments to patients.

For patients with severe illness, the struggle often goes beyond physical symptoms. A 2023 study highlighted how illness can lead to feelings of alienation, loss of physical and mental control, and deep depression. Patients often feel unheard and unseen by busy healthcare providers, intensifying their stress and anxiety. Many patients turn to clinical trials as an opportunity not only to contribute to medical advances but also to receive more attention and personalized care. For these patients, it’s not just about treatment—it’s about being acknowledged as a person with a story and personal needs, not just a diagnosis. By reducing manual busywork in the data collection and transfer process, Yonalink gives staff more time to focus on their patients and to provide the attention and personal care that patients so deeply crave and deserve. Are you ready to provide a better experience for your trial patients and staff? Let's discuss how Yonalink can help. https://lnkd.in/dfAvYnqj